Long-term data confirm efficacy of cholesterol-lowering drug Leqvio
Basel-based pharmaceutical giant Novartis has published new data from a long-term study of its cholesterol-lowering drug Leqvio. The results are in line with earlier findings and confirm the favourable safety profile of the drug, Novartis announced on Monday afternoon.
+Novartis aims for October spin-off of Sandoz unit
Specifically, the results of the open-label extension study, called Orion-8, showed that twice-yearly treatment with Leqvio in addition to statin therapy consistently lowered low-density lipoprotein cholesterol (LDL-C). The duration of treatment was six years, according to Novartis.
More
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
More
The citizenship obstacle course facing spouses of Swiss Abroad
More
‘Swiss engineering at its best’: the steepest cable car in the world
More
Audrey Hepburn’s Swiss villa on market for CHF19 million
More
Foreign aid cuts: where does Switzerland stand?
More
Swiss voters reject green overhaul of economy
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.